On November 5, 2018 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that the Company will have two oral presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 33rd Annual Meeting to be held November 9-11, 2018 in Washington, D.C (Press release, Mirati, NOV 5, 2018, View Source [SID1234530718]). Preliminary biomarker data from the ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO) in non-small cell cancer lung (NSCLC) patients will be presented along with a data update in the ongoing Phase 2 clinical trial of mocetinostat in combination with durvalumab (IMFINZI) in NSCLC patients.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
SITC Oral Presentation Details:
Title: Preliminary Biomarker Analysis of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor
Presentation Date and Time: Saturday, November 10th at 12:35pm EST – 1:35pm EST
Presenter: Kai He, M.D., Ph.D.
Poster Number: P385
Session Title: Rapid Oral Abstracts
Location: Hall E
Poster Presentation Hours: Friday, November 9th from 12:45 p.m. EST – 2:15 p.m. EST and 6:30 p.m. EST – 8:00 p.m. EST
Title: Phase 2 Trial of Mocetinostat in Combination with Durvalumab in NSCLC Patients with Progression on Prior Checkpoint Inhibitor Therapy
Presentation Date and Time: Sunday, November 11th at 8:05 a.m. EST – 10:15 a.m. EST
Presenter: Manish Patel, D.O.
Poster Number: O27
Session Title: Clinical Trials
Location: Hall E
Poster Presentation Hours: Friday, November 9th from 12:45 p.m. EST – 2:15 p.m. EST and 6:30 p.m. EST – 8:00 p.m. EST
About Sitravatinib
Sitravatinib is a spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET. As an immuno-oncology agent, sitravatinib is being evaluated in combination with nivolumab (OPDIVO), an anti-PD-1 checkpoint inhibitor, in patients who have experienced documented disease progression following treatment with a checkpoint inhibitor. Sitravatinib’s potent inhibition of TAM and split family RTKs may overcome resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment, enhancing antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation.
Sitravatinib is also being evaluated as a single agent in a Phase 1b expansion clinical trial enrolling patients whose tumors harbor specific mutations in the CBL protein. When CBL is inactivated by mutation, multiple RTKs, including TAM, VEGFR2 and KIT, are dysregulated and may act as oncogenic tumor drivers in NSCLC and melanoma. Sitravatinib potently inhibits these RTKs and is being investigated as a treatment option for cancer patients with CBL mutations.
About Mocetinostat
Mocetinostat is an oral, Class I and IV selective histone deacetylase (HDAC) inhibitor. Inhibition of histone acetylation is predicted to enhance the recognition of tumor cells by anti-tumor T cells and reverse immunosuppressive factors in the tumor microenvironment. Mocetinostat is being evaluated in a Phase 2 clinical trial in combination with durvalumab (IMFINZI) in NSCLC patients who have experienced disease progression following prior treatment with checkpoint inhibitor.